1. Name and Address of Reporting Person:
Pascoe Richard W
C/O KEMPHARM, INC.
1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION FL 34747

2. Issuer Name and Ticker or Trading Symbol:
KEMPHARM, INC [KMPH]

3. Date of Earliest Transaction (Month/Day/Year):
06/19/2020

4. If Amendment, Date of Original Filed (Month/Day/Year):

5. Relationship of Reporting Person(s) to Issuer:
X Director
10% Owner

6. Individual or Joint/Group Filing (Check Applicable Line):
X Form filed by One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 3. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 5) | 5. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 6. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 7. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 8. Ownership Percent:
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>StockOption (right to buy)</td>
<td>06/19/2020</td>
<td></td>
<td></td>
<td>A</td>
<td>30,000</td>
<td>50</td>
<td>30,000</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>StockOption (right to buy)</td>
<td>06/19/2020</td>
<td>A</td>
<td></td>
<td>30,000</td>
<td>06/18/2030</td>
<td>Common Stock</td>
<td>30,000</td>
<td>50</td>
<td>30,000</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. The exercise price is equal to the closing price of the Issuer's common stock on the OTCQB Venture Market on the date of grant, June 19, 2020.
2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's fourth amended and restated non-employee director compensation policy.
3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

/s/ Timothy J. Sangiovanni,
Attorney-in-Fact for Richard W. Pascoe

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.